Based on the results obtained showing increased expression of intestinal bradykinin receptors in C. rodentium-treated TLR9 KO mice, the effects of R715 and HOE 140, selective antagonists of Bdkrb1 and 2, respectively, for treatment of PI-IBS were examined. This evidence concerns the gene BDKRB1 and irritable bowel syndrome.